Chelation Therapy Using Static Magnetic Field
Preprint
Abstract
Static magnetic field (SMF) is reported to mimic chelation agents. In thalassemia blood, SMF minimizes iron overloading effect. In such cells ROS level is reduced, in presence of moderate strength (70mT). Pilot study on transfusion dependent thalassemia, thalassemia carriers and normal red blood clearly indicate the differential effects of SMF on thalassemia, thalassemia carrier and normal cells. SMF also reduces ROS induced DNA damage in lymphocytes. A comparative study on the iron chelating drug deferasirox and SMF treated lymphocytes further confirm our main thesis. This non-invasive therapeutic regime for hemochromatosis may serve the dual purpose of treating, iron overloading and minimizing, cellular damage by lowering the ROS level.Keywords
This publication has 13 references indexed in Scilit:
- Small conjugate-based theranostic agents: an encouraging approach for cancer therapyChemical Society Reviews, 2015
- Current approach to iron chelation in childrenBritish Journal of Haematology, 2014
- Theranostic Magnetic NanoparticlesAccounts of Chemical Research, 2011
- Reducing blood viscosity with magnetic fieldsPhysical Review E, 2011
- Iron loading and its clinical implicationsAmerican Journal of Hematology, 2007
- Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi‐center study of iron overloadAmerican Journal of Hematology, 2007
- Severe infections in thalassaemic patients: prevalence and predisposing factorsBritish Journal of Haematology, 2006
- Nanoscale Size Effect of Magnetic Nanocrystals and Their Utilization for Cancer Diagnosis via Magnetic Resonance ImagingJournal of the American Chemical Society, 2005
- Disorders of Iron MetabolismNew England Journal of Medicine, 1999
- BiomagneticsIEEE Transactions on Magnetics, 1972